慢性淋巴细胞白血病治疗研究最新进展

Research Progress in Treatment of Chronic Lymphocytic Leukemia——Review

慢性淋巴细胞白血病(CLL)是好发于中老年人群的一种低级别淋巴增殖性肿瘤,早期精准干预可以有效改善CLL患者的临床预后。既往治疗方案主要以化学治疗为主,随着分子生物学发展及免疫靶向药物的不断问世,针对B细胞受体信号通路的靶向药物在CLL诊治路径中表现出较高的临床应用价值。CAR-T等细胞免疫疗法也为复发难治CLL患者带来了希望。异基因造血干细胞移植和多药联合手段也在临床实践中表现出较为显著的效果。本文旨在就慢性淋巴细胞白血病的最新治疗研究进展作一综述。

Chronic lymphocytic leukemia(CLL)is a low-grade lymphoproliferative tumor that occurs frequently in middle-aged and elderly people.Early and precise intervention can effectively improve the clinical prognosis of CLL patients.In the past,chemotherapy was the main treatment plan.With the development of molecular biology and the continuous advent of immune targeting drugs,targeted drugs targeting B cell receptor signaling pathway have shown high clinical application value in the diagnosis and treatment path of CLL.Cellular immunotherapies such as CAR-T also offer hope for patients with relapsed and refractory CLL.Allogeneic hematopoietic stem cell transplantation and multi-drug combination have also shown remarkable results in clinical practice.The purpose of this article is to review the latest research progress in the treatment of CLL.